U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS
This repository is under review for potential modification in compliance with Administration directives.

Approval Year

2014
503
Name Type Language
PEMBROLIZUMAB
DASH   INN   USAN   VANDF   WHO-DD  
USAN   INN  
Official Name English
pembrolizumab [INN]
Preferred Name English
PEMBROLIZUMAB [USAN]
Common Name English
PEMBROLIZUMAB [MI]
Common Name English
KEYTRUDA
Brand Name English
IMMUNOGLOBULIN G4, ANTI-(HUMAN PROTEIN PDCD1 (PROGRAMMED CELL DEATH 1)) (HUMAN-MUS MUSCULUS MONOCLONAL HEAVY CHAIN), DISULFIDE WITH HUMAN-MUS MUSCULUS MONOCLONAL LIGHT CHAIN, DIMER
Common Name English
KEYLYNK-010 COMPONENT PEMBROLIZUMAB
Code English
SCH-900475
Code English
LAMBROLIZUMAB
Common Name English
PEMBROLIZUMAB [VANDF]
Common Name English
MK 7684A COMPONENT PEMBROLIZUMAB
Common Name English
PEMBROLIZUMAB [PURPLE BOOK CDER]
Common Name English
MK-3475
Code English
MK-1308A COMPONENT PEMBROLIZUMAB
Common Name English
Pembrolizumab [WHO-DD]
Common Name English
PEMBROLIZUMAB [JAN]
Common Name English
Classification Tree Code System Code
FDA ORPHAN DRUG 705319
Created by admin on Mon Mar 31 21:24:15 GMT 2025 , Edited by admin on Mon Mar 31 21:24:15 GMT 2025
FDA ORPHAN DRUG 502415
Created by admin on Mon Mar 31 21:24:15 GMT 2025 , Edited by admin on Mon Mar 31 21:24:15 GMT 2025
FDA ORPHAN DRUG 570816
Created by admin on Mon Mar 31 21:24:15 GMT 2025 , Edited by admin on Mon Mar 31 21:24:15 GMT 2025
FDA ORPHAN DRUG 578717
Created by admin on Mon Mar 31 21:24:15 GMT 2025 , Edited by admin on Mon Mar 31 21:24:15 GMT 2025
FDA ORPHAN DRUG 576917
Created by admin on Mon Mar 31 21:24:15 GMT 2025 , Edited by admin on Mon Mar 31 21:24:15 GMT 2025
FDA ORPHAN DRUG 511715
Created by admin on Mon Mar 31 21:24:15 GMT 2025 , Edited by admin on Mon Mar 31 21:24:15 GMT 2025
FDA ORPHAN DRUG 548216
Created by admin on Mon Mar 31 21:24:15 GMT 2025 , Edited by admin on Mon Mar 31 21:24:15 GMT 2025
WHO-ATC L01XC18
Created by admin on Mon Mar 31 21:24:15 GMT 2025 , Edited by admin on Mon Mar 31 21:24:15 GMT 2025
FDA ORPHAN DRUG 481715
Created by admin on Mon Mar 31 21:24:15 GMT 2025 , Edited by admin on Mon Mar 31 21:24:15 GMT 2025
FDA ORPHAN DRUG 605417
Created by admin on Mon Mar 31 21:24:15 GMT 2025 , Edited by admin on Mon Mar 31 21:24:15 GMT 2025
FDA ORPHAN DRUG 495415
Created by admin on Mon Mar 31 21:24:15 GMT 2025 , Edited by admin on Mon Mar 31 21:24:15 GMT 2025
FDA ORPHAN DRUG 381012
Created by admin on Mon Mar 31 21:24:15 GMT 2025 , Edited by admin on Mon Mar 31 21:24:15 GMT 2025
FDA ORPHAN DRUG 513115
Created by admin on Mon Mar 31 21:24:15 GMT 2025 , Edited by admin on Mon Mar 31 21:24:15 GMT 2025
EMA ASSESSMENT REPORTS KEYTRUDA (AUTHORIZED: MELANOMA)
Created by admin on Mon Mar 31 21:24:15 GMT 2025 , Edited by admin on Mon Mar 31 21:24:15 GMT 2025
NDF-RT N0000191260
Created by admin on Mon Mar 31 21:24:15 GMT 2025 , Edited by admin on Mon Mar 31 21:24:15 GMT 2025
NCI_THESAURUS C128037
Created by admin on Mon Mar 31 21:24:15 GMT 2025 , Edited by admin on Mon Mar 31 21:24:15 GMT 2025
Code System Code Type Description
FDA UNII
DPT0O3T46P
Created by admin on Mon Mar 31 21:24:15 GMT 2025 , Edited by admin on Mon Mar 31 21:24:15 GMT 2025
PRIMARY
DRUG CENTRAL
4924
Created by admin on Mon Mar 31 21:24:15 GMT 2025 , Edited by admin on Mon Mar 31 21:24:15 GMT 2025
PRIMARY
NDF-RT
N0000191259
Created by admin on Mon Mar 31 21:24:15 GMT 2025 , Edited by admin on Mon Mar 31 21:24:15 GMT 2025
PRIMARY Programmed Death Receptor-1-directed Antibody Interactions [MoA]
DAILYMED
DPT0O3T46P
Created by admin on Mon Mar 31 21:24:15 GMT 2025 , Edited by admin on Mon Mar 31 21:24:15 GMT 2025
PRIMARY
MERCK INDEX
m11762
Created by admin on Mon Mar 31 21:24:15 GMT 2025 , Edited by admin on Mon Mar 31 21:24:15 GMT 2025
PRIMARY
DRUG BANK
DB09037
Created by admin on Mon Mar 31 21:24:15 GMT 2025 , Edited by admin on Mon Mar 31 21:24:15 GMT 2025
PRIMARY
CAS
1422183-02-5
Created by admin on Mon Mar 31 21:24:15 GMT 2025 , Edited by admin on Mon Mar 31 21:24:15 GMT 2025
SUPERSEDED
INN
9798
Created by admin on Mon Mar 31 21:24:15 GMT 2025 , Edited by admin on Mon Mar 31 21:24:15 GMT 2025
PRIMARY
LACTMED
Pembrolizumab
Created by admin on Mon Mar 31 21:24:15 GMT 2025 , Edited by admin on Mon Mar 31 21:24:15 GMT 2025
PRIMARY
SMS_ID
100000157957
Created by admin on Mon Mar 31 21:24:15 GMT 2025 , Edited by admin on Mon Mar 31 21:24:15 GMT 2025
PRIMARY
CAS
1374853-91-4
Created by admin on Mon Mar 31 21:24:15 GMT 2025 , Edited by admin on Mon Mar 31 21:24:15 GMT 2025
PRIMARY
RXCUI
1547545
Created by admin on Mon Mar 31 21:24:15 GMT 2025 , Edited by admin on Mon Mar 31 21:24:15 GMT 2025
PRIMARY RxNorm
IUPHAR
7499
Created by admin on Mon Mar 31 21:24:15 GMT 2025 , Edited by admin on Mon Mar 31 21:24:15 GMT 2025
PRIMARY
ChEMBL
CHEMBL2364654
Created by admin on Mon Mar 31 21:24:15 GMT 2025 , Edited by admin on Mon Mar 31 21:24:15 GMT 2025
PRIMARY
USAN
ZZ-165
Created by admin on Mon Mar 31 21:24:15 GMT 2025 , Edited by admin on Mon Mar 31 21:24:15 GMT 2025
PRIMARY
HSDB
8257
Created by admin on Mon Mar 31 21:24:15 GMT 2025 , Edited by admin on Mon Mar 31 21:24:15 GMT 2025
PRIMARY
WIKIPEDIA
Pembrolizumab
Created by admin on Mon Mar 31 21:24:15 GMT 2025 , Edited by admin on Mon Mar 31 21:24:15 GMT 2025
PRIMARY
ChEMBL
CHEMBL3137343
Created by admin on Mon Mar 31 21:24:15 GMT 2025 , Edited by admin on Mon Mar 31 21:24:15 GMT 2025
PRIMARY
EVMPD
SUB167136
Created by admin on Mon Mar 31 21:24:15 GMT 2025 , Edited by admin on Mon Mar 31 21:24:15 GMT 2025
PRIMARY
NCI_THESAURUS
C106432
Created by admin on Mon Mar 31 21:24:15 GMT 2025 , Edited by admin on Mon Mar 31 21:24:15 GMT 2025
PRIMARY
ACTIVE MOIETY
PEMBROLIZUMAB
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966